Close Menu

NEW YORK – Genetron Health announced Thursday a strategic partnership with Thermo Fisher Scientific to commercialize next-generation sequencing-based diagnostics in China.

The deal will bring the Genetron S5, which is based on Thermo Fisher's Ion GeneStudio S5 instrument for targeted NGS, to China's public hospitals for use in cancer diagnostics, genetic disease diagnosis, microbial testing, and reproductive health testing, among other uses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.